Daily Cardiology Research Analysis
Three impactful cardiology studies span basic-to-clinical translation. A rigorous genetic-mechanistic study links primary cilia disruption (CDKL1 variants) to thoracic aortic aneurysm/dissection, a cross-trial modeling analysis projects substantial lifetime benefit from combined SGLT2i+nsMRA±ARNI therapy in HFmrEF/HFpEF, and an RCT shows renal FFR guidance halves unnecessary stenting while preserving blood pressure control.
Summary
Three impactful cardiology studies span basic-to-clinical translation. A rigorous genetic-mechanistic study links primary cilia disruption (CDKL1 variants) to thoracic aortic aneurysm/dissection, a cross-trial modeling analysis projects substantial lifetime benefit from combined SGLT2i+nsMRA±ARNI therapy in HFmrEF/HFpEF, and an RCT shows renal FFR guidance halves unnecessary stenting while preserving blood pressure control.
Research Themes
- Ciliopathy and aortopathy genetics
- Combination pharmacotherapy in HFpEF/HFmrEF
- Physiology-guided revascularization in renovascular hypertension
Selected Articles
1. CDKL1 variants affecting ciliary formation predispose to thoracic aortic aneurysm and dissection.
Through patient sequencing and multi-system validation, the authors identify CDKL1 kinase variants as new TAAD risk alleles that disrupt primary cilia, protein interactions, and p38 MAPK/VEGF signaling. Zebrafish models recapitulate vascular defects and are rescued only by wild-type CDKL1, establishing causality and implicating ciliary biology in aortopathy.
Impact: This is among the first demonstrations linking primary cilia dysregulation to human TAAD with functional and in vivo evidence, expanding the molecular taxonomy of aortopathy and opening avenues for genetic diagnosis and pathway-targeted therapies.
Clinical Implications: Suggests adding CDKL1 to genetic panels for TAAD and highlights cilia-related pathways (e.g., p38 MAPK/VEGF) as potential therapeutic targets; supports surveillance strategies in families with CDKL1 variants.
Key Findings
- Heterozygous CDKL1 missense variants were identified in 6 TAAD patients from 3 families via exome/panel sequencing.
- Variants impaired CDKL1 kinase function, altered interactions with ciliary transport proteins, and disrupted cilia formation/length and localization.
- Cdkl1 knockdown/knockout in zebrafish caused vascular malformations and aortic dilation; rescue required wild-type CDKL1 RNA, not mutant.
- Signaling alterations included p38 MAPK and VEGF pathway perturbations, linking ciliary dysfunction to aortopathy.
Methodological Strengths
- Human genetics integrated with in vivo zebrafish models and cellular assays to establish causality.
- Rescue experiments using wild-type vs mutant CDKL1 RNA provide strong functional validation.
Limitations
- Family-based sample size is modest and penetrance/expressivity across broader populations remains to be defined.
- Therapeutic modulation of ciliary pathways was not tested in mammalian TAAD models.
Future Directions: Expand genotype-phenotype studies across diverse TAAD cohorts, develop mammalian models for CDKL1-targeted therapeutics, and explore pharmacologic modulation of ciliary signaling in aortopathy.
Genetic factors are fundamental in the etiology of thoracic aortic aneurysm and dissection (TAAD), but the genetic cause is detected in only about 30% of cases. To define unreported TAAD-associated sequence variants, exome and gene panel sequencing was performed in 323 patients. We identified heterozygous CDKL1 variants [c.427T>C p.(Cys143Arg), c.617C>T p.(Ser206Leu), and c.404C>T p.(Thr135Met)] in 6 patients from 3 families with TAAD spectrum disorders. CDKL1 encodes a protein kinase involved in ciliary biology. Amino acid substitutions were predicted to affect CDKL1 catalytic activity or protein binding properties. CDKL1 was expressed in vascular smooth muscle cells in normal and diseased human aortic wall tissue. Cdkl1 knockdown and transient knockout in zebrafish resulted in intersomitic vessel (ISV) malformations and aortic dilation. Coinjection of human CDKL1wild-type RNA, but not CDKL1Cys143Arg and CDKL1Ser206Leu RNA, rescued ISV malformations. All variants affected CDKL1 kinase function and profiling data, and altered protein-protein binding properties, particularly with ciliary transport molecules. Expression of CDKL1 variants in heterologous cells interfered with cilia formation and length, CDKL1 localization, and p38 MAPK and Vegf signaling. Our data suggest a role of CDKL1 variants in the pathogenesis of TAAD spectrum disorders. The association between primary cilia dysregulation and TAAD expands our knowledge of the underlying molecular pathophysiology.
2. Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction.
Using cross-trial modeling of DELIVER, FINEARTS-HF, and PARAGON-HF, combined SGLT2i+nsMRA therapy is projected to reduce CV death or first HF event by 31% overall; adding ARNI for LVEF <60% yields a 39% reduction. Event-free survival gains (3.6–4.9 years) are projected across ages 55–85 with early, sustained combination therapy.
Impact: Provides a quantitative framework for lifetime benefit with combination therapy in HFmrEF/HFpEF, informing treatment strategies beyond single-agent effects and potentially shaping guideline adoption of multi-drug regimens.
Clinical Implications: Supports early initiation and maintenance of SGLT2i+nsMRA (and ARNI when LVEF <60%) in HFmrEF/HFpEF to maximize event-free survival; encourages clinicians to consider multidrug foundational therapy rather than sequential monotherapy.
Key Findings
- Modeled combined SGLT2i+nsMRA therapy lowered CV death or first HF event risk by 31% (HR 0.69; 95% CI 0.59–0.81) across HFmrEF/HFpEF.
- Adding ARNI (for LVEF <60%) further lowered risk by 39% (HR 0.61; 95% CI 0.48–0.77).
- Projected event-free survival gains of 3.6 years (SGLT2i+nsMRA) and 4.9 years (SGLT2i+nsMRA+ARNI) at age 65; benefits span ages 55–85.
Methodological Strengths
- Cross-trial synthesis leveraging large contemporary HFpEF/HFmrEF RCTs.
- Transparent reporting of hazard ratios and projected event-free survival across age strata.
Limitations
- Not a randomized evaluation of combination therapy; projections rely on modeling assumptions across trials.
- Heterogeneity between source trials and potential overlapping populations may influence estimates.
Future Directions: Prospective pragmatic trials to validate multidrug foundational therapy in HFmrEF/HFpEF and research on sequencing, tolerability, and cost-effectiveness across patient phenotypes.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) finerenone have each been shown to individually improve heart failure events among patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Moreover, the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan has been shown to improve outcomes in patients with HFmrEF/HFpEF with a left ventricular ejection fraction (LVEF) below normal (<60%). However, the expected benefits of the combined use of these agents with long-term administration are not well defined. Here, in this cross-trial analysis of DELIVER, FINEARTS-HF and PARAGON-HF, combined use of SGLT2i and nsMRA therapies was estimated to reduce the risk of cardiovascular death or first worsening heart failure event by 31% in the overall population (hazard ratio 0.69; 95% confidence interval 0.59-0.81), while combined use of SGLT2i, nsMRA and ARNI therapies was estimated to reduce risk by 39% in patients with HFmrEF/HFpEF and an LVEF <60% (hazard ratio 0.61; 95% confidence interval 0.48-0.77). With long-term use, combined SGLT2i and nsMRA therapies in a 65-year-old patient with HFmrEF/HFpEF, or combined SGLT2i, nsMRA and ARNI therapies in a 65-year-old patient with an LVEF <60%, were projected to afford 3.6 (2.0-5.2) or 4.9 (2.5-7.3) additional years free from cardiovascular death or a heart failure event, respectively. Combined therapy was estimated to result in meaningful gains in event-free survival across a broad age range, from 55 to 85 years. Among patients with HFmrEF and HFpEF, the potential aggregated long-term treatment effects of early combination medical therapy with SGLT2i and nsMRA (and ARNI in selected individuals) are projected to be substantial.
3. Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial.
In a randomized trial of 101 ARAS patients, renal FFR-guided strategy halved stenting without compromising BP outcomes overall. Patients with FFR <0.80 derived significant reductions in ambulatory systolic BP and antihypertensive medication burden from stenting, while those with FFR ≥0.80 did not, supporting physiology-guided revascularization.
Impact: Addresses a long-standing controversy in ARAS by showing that functional assessment identifies who benefits from stenting while avoiding unnecessary procedures, with immediate implications for interventional practice and resource use.
Clinical Implications: Adopt renal FFR (fractional flow reserve) to guide revascularization: reserve stenting for FFR <0.80; manage FFR ≥0.80 medically, reducing procedural exposure without sacrificing blood pressure outcomes.
Key Findings
- FFR-guided strategy reduced stenting rate from 100% to 46% versus angiography guidance.
- No overall difference in 3-month changes of daytime ambulatory systolic BP or antihypertensive medication index between strategies.
- Stenting benefited patients with FFR <0.80 (−6.2 mmHg DMSBP; −3.1 reduction in medication index) but not those with FFR ≥0.80.
Methodological Strengths
- Prospective randomized design with prespecified functional threshold (FFR <0.80).
- Clinically relevant endpoints (ambulatory BP and medication burden) and trial registration.
Limitations
- Modest sample size and short 3-month primary follow-up limit detection of downstream clinical events.
- Single-parameter FFR threshold may not capture all hemodynamic nuances of renal stenosis.
Future Directions: Larger, longer RCTs powered for renal/cardiovascular outcomes and cost-effectiveness analyses of physiology-guided strategies.
BACKGROUND AND AIMS: The optimal therapy for patients with atherosclerotic renal artery stenosis (ARAS) remains unresolved. This study compared the efficacy of renal fractional flow reserve (FFR)-guided revascularization and traditional angiography-guided revascularization. METHODS: In total, 101 patients with ARAS and hypertension were randomly assigned to either the FFR-guided or angiography-guided group (ClinicalTrials.gov identifier: NCT05732077). Stenting was performed in the angiography-guided group regardless of FFR, whereas stenting was only performed in the FFR-guided group for patients with FFR < 0.80. The primary endpoints were the percentage changes in ambulatory daytime mean systolic blood pressure (DMSBP) and composite index of antihypertensive medicines (CIAHM) after 3 months. RESULTS: The percentage changes in DMSBP (4% [-2%, 11%] vs 4% [-3%, 10%]; P = .97) and CIAHM (0% [0%, 3%] vs 1% [0%, 4%]; P = .33) did not differ between groups. However, the rate of stenting was significantly lower in the FFR-guided group (46.0% vs 100.0%, P < .01). Moreover, compared with the findings in patients with FFR ≥ 0.80 who did not receive stenting, stenting was beneficial in patients with FFR < 0.80 (adjusted mean DMSBP reduction, 6.2 [95% confidence interval {CI}, 0.6-11.9] mmHg; mean CIAHM reduction, 3.1 [95% CI, 1.5-4.7]), but not in those with FFR ≥ 0.80 (1.4 [95% CI, -4.5-7.2] mmHg, and 0.7 [95% CI, -1.1-2.5], respectively). CONCLUSIONS: FFR-guided revascularization significantly reduced unnecessary stenting compared with angiography-guided revascularization. Both blood pressure and antihypertensive medication usage decreased significantly after stenting in patients with FFR < 0.80.